NCT00233571View on ClinicalTrials.gov

A Long Term Roll-over Study to Investigate the Efficacy and Safety of Adalimumab Given Long-term to Patients With Rheumatoid Arthritis

PHASE3CompletedINTERVENTIONAL
Enrollment

796

Participants

Timeline

Start Date

June 30, 2000

Primary Completion Date

June 30, 2006

Study Completion Date

June 30, 2006

Conditions
Rheumatoid Arthritis
Interventions
BIOLOGICAL

Adalimumab 40 mg subcutaneous (SC) every other week (EOW)

Sponsors

Lead Sponsor

Abbott
All Listed Sponsors
lead

Abbott

INDUSTRY

NCT00233571 - A Long Term Roll-over Study to Investigate the Efficacy and Safety of Adalimumab Given Long-term to Patients With Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter